Peptides 101: BPC-157, TB-500, GHK-Cu and the NZ Context

Research peptides are not established shortcuts to recovery or longevity. Medsafe warns that unapproved online products, including BPC-157 and TB-500, lack good evidence for advertised benefits and safety. 1

What are peptides?

Peptides are short chains of amino acids. Some act as biological signals, while synthetic versions can reproduce or modify naturally occurring sequences.

Their effects are not interchangeable. The exact molecule, formulation and route matter when interpreting research. A familiar peptide name does not guarantee an identical product. 3

Read evidence in three stages: what happened in cells, what happened in animals, and what happened in people. A proposed mechanism can justify further research without establishing a useful treatment.

BPC-157: tissue repair claims and human evidence

BPC-157 is a synthetic 15-amino-acid peptide commonly described as originating from a gastric protective protein. That description does not establish safety when it is administered as a drug. 2

Research interest includes wound, tendon and ligament repair, alongside protection against gastrointestinal injury. These findings are predominantly preclinical, rather than evidence of dependable recovery in people. 2

Proposed pathways include growth-factor signalling, nitric oxide and angiogenesis, meaning new blood-vessel formation. FDA reviewers emphasise that its molecular targets and mechanisms remain uncertain. 2

Human research exists, but includes small studies and incompletely reported findings. It does not establish that BPC-157 reliably heals injuries or treats gut conditions. 2

For example, an intravenous safety pilot involved just two people. Such short-term observations cannot establish long-term safety or detect uncommon harms. 3

TB-500: do not confuse the fragment with the full peptide

TB-500 is commonly used to describe a synthetic seven-amino-acid fragment of thymosin beta-4. It is not the same molecule as full-length thymosin beta-4. 3

Claims about cell migration, inflammation and tissue remodelling often draw on the parent peptide's research. Those findings cannot simply be assigned to TB-500. 3

In its July 2026 assessment, the FDA identified no clinical studies or human exposure data for TB-500. Recovery anecdotes do not fill that gap. 3

GHK-Cu: topical research is not injectable evidence

GHK-Cu is a copper-binding tripeptide studied in skin care. Human topical research exists, but it does not establish broad claims about collagen synthesis, wound healing or whole-body rejuvenation. 4

In a randomised study after CO2 laser resurfacing, 13 people completed follow-up. Adding GHK-Cu produced no significant objective advantage in redness, wrinkles or overall skin quality. 4

Patient satisfaction was higher in the GHK-Cu group. That is worth reporting, but it is different from demonstrating faster healing or an objective improvement in skin structure. 4

Injectable GHK-Cu needs separate scrutiny. The FDA identifies limited human safety data and possible immune reactions associated with aggregation and peptide-related impurities. 5

Epithalon, MOTS-C and Semax

Epithalon, also called Epitalon, is a synthetic tetrapeptide studied in ageing research. Experiments have reported changes in telomerase activity and telomere length in human cell lines. 6

Human cells in a laboratory are not a human longevity trial. These findings do not show that taking Epithalon extends life or prevents age-related disease. 6

MOTS-C is a mitochondrial-derived peptide studied in metabolic regulation. A 2021 paper found that naturally occurring MOTS-C increased after exercise in humans and tested administered MOTS-C in mice. 7

These are different experiments. An exercise-related rise in the body's own peptide does not show that injecting it improves human fitness, glucose regulation or longevity. 7

Semax is a synthetic ACTH-related peptide studied for brain-related effects. Medsafe describes limited clinical research and uncertainty about adverse and long-term effects. 8

NZ regulatory context

Medsafe's 21 May 2026 warning names BPC-157 and TB-500 among unapproved online products. Many peptide products are prescription medicines; unauthorised import, supply or possession can be unlawful. 1

A label saying “for research purposes only” does not authorise sale or use in people. Nor does online availability establish approval. 1

Unapproved does not mean that every possible medical use is prohibited. The Medicines Act provides specific lawful pathways involving authorised prescribers, supply requirements and informed consent. 9

An unapproved product is also different from an approved medicine used off-label. Neither a prescription nor lawful supply proves that a proposed use is effective. 9

Inception Nutrition does not sell, prescribe or recommend specific peptides. This guide is educational, not an administration or dosing protocol.

Practical steps before acting on a peptide claim

Ask these questions before accepting a claimed benefit:

Was the exact molecule studied, or a related peptide?
Did people receive it, or were researchers measuring a naturally occurring substance?
Was the route the same: topical, oral, nasal or injectable?
Were meaningful outcomes measured against a comparison group?
How long were adverse effects monitored?

For recovery goals, start by reviewing food intake, protein-containing meals, sleep, training load and any rehabilitation plan. Use our recovery nutrition guide to organise that discussion.

Treat these as separate priorities, not preparation for an experimental peptide protocol. Persistent injury or unexplained symptoms warrant assessment rather than self-treatment.

If you have used an unapproved injectable and feel unwell, seek medical advice immediately. Tell the clinician what you took and bring the packaging or product details. 1

For related reading, see NAD+ and cellular ageing and biohacking in New Zealand.

References

1.Medsafe. Consumer advisory: Unapproved peptide products health warning. 21 May 2026. Source

2.US Food and Drug Administration. FDA Briefing Document for BPC-157-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee, July 2026.[Scientific assessment, not a final compounding decision.] Source

3.US Food and Drug Administration. July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee: FDA Presentations.[Includes BPC-157 and TB-500 evidence assessments.] Source

4.Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. 2006. Institutional publication record, Creighton University.[Randomised study with 13 participants completing follow-up.] Source

5.US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.[Includes route-specific safety concerns for injectable GHK-Cu.] Source

6.Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. 2025.[Laboratory cell-line study.] PMID 40908429

7.MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470.[Human exercise observations and mouse intervention experiments must be interpreted separately.] doi:10.1038/s41467-020-20790-0

8.Medsafe. Peptide classification submission to the 74th Medicines Classification Committee meeting. 2025.[Used for Semax background, not as confirmation of current classifications.] Source

9.Medsafe. Use of Unapproved Medicines and Use of approved Medicines for an unapproved purpose. Revised 12 December 2025. Source

Quick answers

What does BPC-157 actually do?

Laboratory research suggests effects on tissue repair and gut injury. Human studies are too limited to establish reliable benefits or long-term safety.

What is the difference between BPC-157 and TB-500?

They are different molecules. BPC-157 has a small human research record. TB-500 is a thymosin beta-4 fragment, and research on the full-length peptide cannot establish the fragment's benefits.

Can I legally buy research peptides in New Zealand?

Online availability does not establish legality. Prescription-medicine supply requires authorisation, and unapproved medicines have specific lawful pathways. A research-only label is not an exemption.

Does topical GHK-Cu research support injecting it?

No. Skin-care studies do not establish injectable benefits or safety. Injectable GHK-Cu has limited human safety data and potential immune-reaction risks.

Can good nutrition make experimental peptides safe?

No evidence establishes that adequate nutrition removes their risks. Review food intake, sleep and training separately, rather than treating them as preparation for a peptide protocol.